Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Orchestra BioMed Holdings (OBIO) FCF Margin (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed FCF Margin for 4 consecutive years, with 1725.9% as the latest value for Q3 2025.

  • On a quarterly basis, FCF Margin fell 33097.0% to 1725.9% in Q3 2025 year-over-year; TTM through Sep 2025 was 2157.31%, a 33736.0% decrease, with the full-year FY2024 number at 1927.48%, down 25339.0% from a year prior.
  • FCF Margin was 1725.9% for Q3 2025 at Orchestra BioMed Holdings, up from 1861.36% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 620.21% in Q1 2022 to a low of 5392.89% in Q4 2024.
  • A 4-year average of 1926.33% and a median of 1725.9% in 2025 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: plummeted -338976bps in 2023, then surged 106354bps in 2024.
  • Orchestra BioMed Holdings' FCF Margin stood at 797.64% in 2022, then tumbled by -425bps to 4187.4% in 2023, then dropped by -29bps to 5392.89% in 2024, then surged by 68bps to 1725.9% in 2025.
  • Per Business Quant, the three most recent readings for OBIO's FCF Margin are 1725.9% (Q3 2025), 1861.36% (Q2 2025), and 1927.19% (Q1 2025).